Literature DB >> 18221598

Evaluation and management of aortic valve and root disease.

John B de Graft-Johnson1, Thomas G Gleason.   

Abstract

Aortic valve disease manifests in the form of stenosis, regurgitation, or some combination, yielding either excessive afterload and/or excessive preload on the left ventricle. Aortic root disease may affect valvular function, causing regurgitation; may simply be coexistent with stenotic aortic valvular disease; or may exist despite normal aortic valve function. Indications for intervening on aortic valve or root disease are determined by the presence of symptoms, by the pathology's impact on left ventricular function, or by the inherent risk of aortic catastrophe (dissection, disruption, or sudden death). Aortic valvular and root diseases are primarily treated by surgical replacement of the pathologic structures. Mechanical aortic valve replacement has long-term durability but requires continuous anticoagulation. Bioprostheses do not require anticoagulation but have more limited durability. Valve-sparing aortic root replacement and aortic valve repair offer the potential for indefinite durability without the need for anticoagulation but are technically more difficult to perform and require more stringent selection criteria based on determining the reparability of an aortic valve. Emerging percutaneous valve technologies offer new hope for patients who are not candidates for aortic valve surgery, but the applicability and durability of percutaneous aortic valves are not yet known. Timely and appropriate intervention in aortic valve and root disease can result in the restoration of a normal life span for patients with aortic valvular and/or root disease.

Entities:  

Year:  2007        PMID: 18221598     DOI: 10.1007/s11936-007-0041-2

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  68 in total

Review 1.  Current perspective on aortic valve repair and valve-sparing aortic root replacement.

Authors:  Thomas G Gleason
Journal:  Semin Thorac Cardiovasc Surg       Date:  2006

2.  Calcific aortic stenosis: a disease ready for prime time.

Authors:  Nalini M Rajamannan
Journal:  Circulation       Date:  2006-11-07       Impact factor: 29.690

3.  Ten years of experience with the modified Ross procedure.

Authors:  P Stelzer; S Weinrauch; R F Tranbaugh
Journal:  J Thorac Cardiovasc Surg       Date:  1998-05       Impact factor: 5.209

4.  Mitroflow synergy prostheses for aortic valve replacement: 19 years experience with 1,516 patients.

Authors:  Kazutomo Minami; Armin Zittermann; Sebastian Schulte-Eistrup; Heinrich Koertke; Reiner Körfer
Journal:  Ann Thorac Surg       Date:  2005-11       Impact factor: 4.330

5.  Mitroflow pericardial valve prosthesis in the aortic position: an analysis of long-term outcome and prognostic factors.

Authors:  K Minami; D Boethig; N Mirow; G Kleikamp; H Koertke; E Godehardt; R Koerfer
Journal:  J Heart Valve Dis       Date:  2000-01

6.  Six-month outcome of transapical transcatheter aortic valve implantation in the initial seven patients.

Authors:  Jian Ye; Anson Cheung; Samuel V Lichtenstein; Sanjeevan Pasupati; Ronald G Carere; Christopher R Thompson; Ajay Sinhal; John G Webb
Journal:  Eur J Cardiothorac Surg       Date:  2006-11-28       Impact factor: 4.191

7.  St. Jude Medical Toronto biologic aortic root prosthesis: early FDA phase II IDE study results.

Authors:  Thomas G Gleason; Tirone E David; Joseph S Coselli; John W Hammon; Joseph E Bavaria
Journal:  Ann Thorac Surg       Date:  2004-09       Impact factor: 4.330

8.  Replacement of the aortic root for acute prosthetic valve endocarditis: prosthetic composite versus aortic allograft root replacement.

Authors:  Rainer G Leyh; Karsten Knobloch; Christian Hagl; Arjang Ruhparwar; Stefan Fischer; Theo Kofidis; Axel Haverich
Journal:  J Thorac Cardiovasc Surg       Date:  2004-05       Impact factor: 5.209

9.  Effectiveness of beta-blockade in experimental chronic aortic regurgitation.

Authors:  Eric Plante; Dominic Lachance; Martin Gaudreau; Marie-Claude Drolet; Elise Roussel; Marie Arsenault; Jacques Couet
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

10.  Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study.

Authors:  Anne B Rossebø; Terje R Pedersen; Christopher Allen; Kurt Boman; John Chambers; Kenneth Egstrup; Eva Gerdts; Christa Gohlke-Bärwolf; Ingar Holme; V Antero Y Kesäniemi; William Malbecq; Christoph Nienaber; Simon Ray; Terje Skjaerpe; Kristian Wachtell; Ronnie Willenheimer
Journal:  Am J Cardiol       Date:  2007-02-15       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.